Table 2.
Association of HOXB13 p.R217C with breast cancer risk in women of European descent.
| N Controls | N Cases | CAF (%) Controls | CAF (%) Cases | OR (95% CI) * | P-value* | |
|---|---|---|---|---|---|---|
| Overall analysis | ||||||
| Europeans | 44,422 | 54,752 | 0.077 | 0.062 | 0.80 (0.48–1.32) | 0.38 |
| Subgroup analysis | ||||||
| Age of diagnosis | ||||||
| < 50 years | 44,422 | 17,669 | 0.077 | 0.045 | 0.38 (0.14–1.01) | 0.05 |
| Menopausal status | ||||||
| Premenopausal | 44,422 | 12,195 | 0.077 | 0.057 | 0.59 (0.24–1.44) | 0.25 |
| Family history | ||||||
| 1st degree relative with BC | 41,909 | 7,531 | 0.069 | 0.013 | 0.21 (0.03–1.53) | 0.12 |
| Second BC | ||||||
| Contralateral BC | 38,346 | 2,137 | 0.076 | 0.047 | 0.43 (0.05–3.43) | 0.43 |
| Receptor status | ||||||
| ER positive | 44,422 | 35,930 | 0.077 | 0.061 | 0.81 (0.46–1.42) | 0.46 |
| ER negative | 44,422 | 9,343 | 0.077 | 0.064 | 0.82 (0.33–2.03) | 0.66 |
| Triple negative | 44,422 | 4,045 | 0.077 | 0.025 | 0.29 (0.04–2.19) | 0.23 |
N, number; CAF, carrier allele frequency; OR, odds ratio; CI, confidence interval; BC, breast cancer; ER, estrogen receptor.
*Dominant genetic model adjusted for country, age and principal components. Not all BCAC studies had info on all variables.